The CWRU/UHC CFAR has established a unique research program with key strengths in international research, Tuberculosis, clinical/translational research and in training. A 16 year close collaboration between CWRU and Makerere University in Uganda has a fostered an effective HIV research infrastructure in Kampala. An effective Fogarty AIDS International Training and Research Program (AIRTP) with at least 30 degree graduates now working in Africa has also promoted an enhanced level of HIV research, HIV care and prevention in Uganda. In Cleveland and Uganda, through the Tuberculosis Research Unit, key studies of epidemiology, pathogenesis and therapy for this leading co-morbid infection are also undertaken by the CFAR. CWRU investigators also are leading novel NCI-sponsored trials of chemotherapy for AIDS-related malignancy in Uganda and Kenya. The CWRU/UHC CFAR has also developed one of the most productive clinical cores in the CFAR network that has supported more than 120 separate clinical and translational research projects during this period of award because of its unique and patient-care/research data base, a linked specimen repository and seamless access to patient volunteers and clinical samples. The CFAR leadership (Steering Committee) that comprises both the Core Directors and leaders of 7 scientific working groups assures that scientific needs and directions of the Center are coordinated with service needs and resources. Six CFAR service cores are each designed to provide CWRU investigators with user-friendly access to state of the art services and facilities both in Cleveland and in Kampala. These cores: Uganda Laboratory, Clinical, Biosafety, Immune Function, Epidemiology/Biostatistics and the new Molecular Virology and Gene Expression are led by experienced investigators and provide quality services that include on-site training and range from access to instrumentation for experienced users to full service performance of assays for infrequent users to meet investigators'individual needs. An Administrative Core coordinates and supports CFAR activities through communications, reporting, accounting and outreach. A Developmental Core provides support and training for new researchers, which is supplemented by generous institutional funding. Strong institutional support is reflected in a nearly $15 million commitment by CWRU and UHC to the CFAR. The CFAR provides added value to the national and international AIDS research effort through its provision of scientific leadership infrastructure dedicated to AIDS research that provides facilities and resources, including some that are not available a other CFARs, and well-organized sponsorship of training, education and outreach.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
3P30AI036219-15S1
Application #
7887144
Study Section
Special Emphasis Panel (ZAI1-AR-A (J3))
Program Officer
Namkung, Ann S
Project Start
1997-04-01
Project End
2010-03-31
Budget Start
2009-08-17
Budget End
2010-03-31
Support Year
15
Fiscal Year
2009
Total Cost
$753,504
Indirect Cost
Name
Case Western Reserve University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Webel, Allison R; Perazzo, Joseph; Longenecker, Christopher T et al. (2018) The Influence of Exercise on Cardiovascular Health in Sedentary Adults With Human Immunodeficiency Virus. J Cardiovasc Nurs 33:239-247
Yan, Junpeng; Shun, Ming-Chieh; Hao, Caili et al. (2018) HIV-1 Vpr Reprograms CLR4DCAF1 E3 Ubiquitin Ligase to Antagonize Exonuclease 1-Mediated Restriction of HIV-1 Infection. MBio 9:
Silver, Nicholas; Paynter, Mary; McAllister, Georgina et al. (2018) Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay. AIDS Res Ther 15:18
Jiang, Wei; Luo, Zhenwu; Martin, Lisa et al. (2018) Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy. Curr HIV Res 16:143-150
Martinez, Leonardo; Handel, Andreas; Shen, Ye et al. (2018) A Prospective Validation of a Clinical Algorithm to Detect Tuberculosis in Child Contacts. Am J Respir Crit Care Med 197:1214-1216
Fitzgerald, Wendy; Freeman, Michael L; Lederman, Michael M et al. (2018) A System of Cytokines Encapsulated in ExtraCellular Vesicles. Sci Rep 8:8973
Dazard, Jean-Eudes; Ishwaran, Hemant; Mehlotra, Rajeev et al. (2018) Ensemble survival tree models to reveal pairwise interactions of variables with time-to-events outcomes in low-dimensional setting. Stat Appl Genet Mol Biol 17:
Mukherjee, Pranab K; Chandra, Jyotsna; Retuerto, Mauricio et al. (2018) Dysbiosis in the oral bacterial and fungal microbiome of HIV-infected subjects is associated with clinical and immunologic variables of HIV infection. PLoS One 13:e0200285
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Tomalka, Amanda G; Resto-Garay, Ivelisse; Campbell, Kerry S et al. (2018) In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells. Front Immunol 9:2552

Showing the most recent 10 out of 539 publications